Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Angiocitoquina. Anticuerpos monoclonales triespecíficos para el tratamiento del carcinoma de células renales

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOFR20150511003
Publicado:
08/12/2015
Caducidad:
08/12/2016
Resumen:
Un equipo de investigación francés ha identificado nuevas dianas terapéuticas para el tratamiento del carcinoma de células renales. Específicamente ha desarrollado nuevos anticuerpos triespecíficos con una sorprendente actividad antitumoral, que pueden sustituir o recetarse como tratamiento de segunda línea para pacientes con resistencia a Avastin® or Sutent®. El objetivo de este nuevo enfoque es aumentar considerablemente la tasa de supervivencia. Se buscan empresas especializadas en oncología y compañías farmacéuticas y biotecnológicas con el fin de establecer acuerdos de licencia y cooperación técnica.

Details

Tittle:
Cytokine Angio - Trispecific monoclonal antibodies for the treatment of renal cell carcinoma
Summary:
A French research team has identified new therapeutic targets for the treatment of renal cell carcinoma. They developed innovative tri-specific antibodies with impressive anti-tumor activity, which could replace or be prescribed as a 2nd line treatment for patients Avastin® or Sutent® resistant. The team is currently looking for an industrial partner interested in a license agreement and/or a technical cooperation agreement.
Description:
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer and current treatments only allow five-year relative survival rates between 46.6-73.3% in the eight major markets. Current treatments only improve the progression-free survival of patients but not their overall survival. This treatment linked with this invention aims to be a second line approach for renal cell carcinoma. Between 40 and 65 percent of patients who progress following first-line therapy receive a second-line treatment. Accordingly, this new approach aims to improve dramatically this survival rate.

A research team of a French academic laboratory showed that cytokines CXCL1, CXCL7 and CXCL8 and CXCL receptors (CXCR1 and CXCR2) are overexpressed in RCC cells and are markers of bad prognosis. The secretion of these CXCL and the presence of their receptors on tumor cells generate autocrine proliferations loops via activation of the ERK/MAP (Extracellular signal-Regulated Kinases/Microtubule-Associated Protein) signaling pathway.

2 tri-specific monoclonal antibodies able to inhibit simultaneously the CXCL1,7 and 8 have been selected among 3840 hybridomas in lab.

CXCL antibodies show a triple effect: anti-inflammatory, anti-angiogenesis and tumor regression. This could be an immunotherapy different from the existing drugs for RCC which target VEGF (Vascular endothelial growth factor) or tyrosine kinases.

The research team is looking for R-Y-D oriented companies focused on oncology : Pharmaceutical companies, Biotechnology companies, of all size small, medium and large companies. License agreement is expected to pursue the development of the pre-clinical phase. Technical cooperation agreement is expected for further developments.
Advantages and Innovations:
This invention has the following advantages:
·Target the tumor cells as well as their tumor-prone environment
·Target the cancer stem cells (express CXCL receptors)
·Same inhibition profile of tumor growth than the gold standard Sutent® on RCC xenografts in mice
·Efficacy on Avastin-resistant RCC tumors
·CXCL1,7 and 8 are trapped simultaneously: no tumor escape
·No predicted off target effect: high specificity of the antibodies (BiacoreTM affinity = 3-40 nM - nanomolar).
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European patent filed in 2013, PCT filed in 2014

Partner sought

Type and Role of Partner Sought:
The research team is looking for industrial companies still engaged in R-Y-D and focused on oncology : Pharmaceutical companies, Biotechnology companies, of all size small, medium and large companies.
These industrial partners are expected to follow the development of the pre-clinical phase (license agreement). The team also plans proof of concept studies about the CXCL antibodies for breast cancer treatment (technical cooperation agreement).

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001015 Productos farmacéuticos / medicamentos